Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
You can call them "frenemies."
Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) are friends when it comes to blockbuster blood thinner Eliquis. But the two big pharma companies are enemies in the oncology and immunology arenas.
How do these collaborators and competitors compare for investors? Here's how Pfizer and Bristol-Myers Squibb (BMS) stack up against each other.
Source: Fool.com
Pfizer Inc. Stock
€26.31
0.650%
With 31 Buy predictions and 4 Sell predictions Pfizer Inc. is one of the favorites of our community.
With a target price of 41 € there is a hugely positive potential of 55.83% for Pfizer Inc. compared to the current price of 26.31 €.